for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ReNeuron Group Plc

RQE.L

Latest Trade

205.00GBp

Change

10.00(+5.13%)

Volume

135,183

Today's Range

205.00

 - 

205.00

52 Week Range

45.00

 - 

335.00

As of on the SEATS (AIM Market) ∙ Minimum 15 minute delay

Pricing

Previous Close
195.00
Open
200.00
Volume
135,183
3M AVG Volume
2.16
Today's High
205.00
Today's Low
205.00
52 Week High
335.00
52 Week Low
45.00
Shares Out (MIL)
31.83
Market Cap (MIL)
62.07
Forward P/E
-3.46
Dividend (Yield %)
--

Latest Developments

More

Reneuron Group Provides AGM Trading Update

Woodford Investment Management Discloses About 32.99% Stake In Reneuron

ReNeuron Expands Exosome IP Portfolio With Key Patent Grants

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ReNeuron Group Plc

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.

Industry

Biotechnology & Drugs

Contact Info

Pencoed Business Park

+44.20.38198400

http://www.reneuron.com/

Executive Leadership

John Edward Berriman

Non-Executive Chairman of the Board

Olav Hellebo

Chief Executive Officer, Director

Michael Elliott Hunt

Chief Financial Officer, Executive Director, Company Secretary

John D. Sinden

Chief Scientific Officer, Executive Director

Sharon Grimster

Vice President Development and General Manager, Wales

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (GBp)

2017

-50.000

2018

-55.700

2019

-45.200

2020(E)

-56.337
Price To Earnings (TTM)
--
Price To Sales (TTM)
1,266.79
Price To Book (MRQ)
2.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-47.57
Return on Equity (TTM)
-38.91

Latest News

BRIEF-Reneuron Group Says Initial Cancer Clinical Trial Application Planned For 2019

* RENEURON GROUP PLC - PHASE I/II STUDY TO BE EXPANDED TO TARGET PATIENTS WITH LESS IMPAIRED VISION AHEAD OF FUTURE PHASE IIB STUDY

BRIEF-Reneuron Group Says ‍Phase II stroke Data Presented At AHA Conference

* POSITIVE LONG-TERM DATA FROM PHASE II CLINICAL TRIAL OF ITS CTX CELL THERAPY CANDIDATE FOR STROKE DISABILITY WAS ACCEPTED FOR PRESENTATION

BRIEF-FDA approves Reneuron's cryopreserved formulation of retinal stem cell therapy candidate​

* FDA approves cryopreserved formulation of reneuron's retinal stem cell therapy candidate Source text for Eikon: Further company coverage: (Reporting By London Bureau)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up